Taisha HALTED and reOPEN -25%
Update Neurogene:
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile
Interim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND Summit
https://ir.neurogene.com/news-relea...-first-patient-dosed-high-dose-cohort-ngn-401
Competitors to Daybue, page-10
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.68 |
Change
-0.100(0.48%) |
Mkt cap ! $2.643B | |||
| Open | High | Low | Value | Volume |
| $20.50 | $20.74 | $20.01 | $5.091M | 247.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156 | $20.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.68 | 256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |